AZOR Drug Patent Profile
✉ Email this page to a colleague
When do Azor patents expire, and when can generic versions of Azor launch?
Azor is a drug marketed by Cosette and is included in one NDA.
The generic ingredient in AZOR is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
Summary for AZOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AZOR |
| What excipients (inactive ingredients) are in AZOR? | AZOR excipients list |
| DailyMed Link: | AZOR at DailyMed |
Pharmacology for AZOR
Anatomical Therapeutic Chemical (ATC) Classes for AZOR
Paragraph IV (Patent) Challenges for AZOR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AZOR | Tablets | amlodipine besylate; olmesartan medoxomil | 10 mg/20 mg and 5 mg/40 mg | 022100 | 1 | 2008-03-31 |
| AZOR | Tablets | amlodipine besylate; olmesartan medoxomil | 5 mg/20 mg and 10 mg/40 mg | 022100 | 1 | 2008-02-11 |
US Patents and Regulatory Information for AZOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-001 | Sep 26, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-004 | Sep 26, 2007 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-002 | Sep 26, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-003 | Sep 26, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AZOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-003 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-004 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-001 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-002 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AZOR
See the table below for patents covering AZOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 573218 | ⤷ Try a Trial | |
| Canada | 2097444 | DERIVES IMIDAZOLE ANTAGONISTES DE L'ANGIOTENSINE II, LEUR PREPARATION ET LEUR USAGE THERAPEUTIQUE (ANGIOTENSIN II ANTAGONIST IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE) | ⤷ Try a Trial |
| South Korea | 0128289 | ⤷ Try a Trial | |
| Germany | 69329982 | ⤷ Try a Trial | |
| Greece | 3035624 | ⤷ Try a Trial | |
| Germany | 122005000051 | ⤷ Try a Trial | |
| Czech Republic | 287764 | Imidazole derivatives, process of their preparation and pharmaceutical preparation in which they are comprised | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AZOR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0503785 | 91330 | Luxembourg | ⤷ Try a Trial | CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS) |
| 0503785 | 20/2009 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, MIT AMLODIPINBESILAT; NAT. REGISTRATION NO/DATE: 1-27894, 1-27895, 1-27896 20081217; FIRST REGISTRATION: NL 100989, 100990, 100991 20080819 |
| 1915993 | C300625 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414 |
| 0503785 | 9/2011 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AUS OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, AMLODIPIN BESILAT UND HYDROCHLOROTHIAZID; NAT. REGISTRATION NO/DATE: 1-30068 - 1-30072 20110216; FIRST REGISTRATION: DE 79810.00.00 - 79814.00.00, UND 79815.00.00 - 79819.00.00 20101216 |
| 0503785 | C300375 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819 |
| 1915993 | 92315 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE |
| 0678503 | C300499 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
